From Barchart: 2024-11-06 07:34:00

Novo Nordisk (NYSE:NVO) saw a 4% pre-market share increase after a strong performance in the first nine months of 2024, with sales up 23% in Danish kroner to DKK 204.7 billion. The diabetes and obesity care segment grew by 25%, driven by demand for GLP-1 treatments like Ozempic and Rybelsus, leading to a 31% sales increase in North America.

The success of Wegovy propelled obesity care sales up by 44%, with Wegovy sales alone increasing by 76% to DKK 38.3 billion. Novo Nordisk’s R&D efforts also showed promise, with the SOUL cardiovascular trial confirming the effectiveness of oral semaglutide in reducing cardiovascular risks for diabetes patients. The company completed a phase 2a trial for obesity treatment candidate monlunabant, with phase 2b trials planned for 2025 to broaden treatment options globally.



Read more at Barchart:: Novo Nordisk Posts Strong 9-Month Growth, Shares G…